ArticlePloS one2012
Molecular and immunological characterization of gluten proteins isolated from oat cultivars that differ in toxicity for celiac disease.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Analysis of oat seed transcriptome with regards to proteins involved in celiac disease.Scientific reports · 2022Article
- Specific Avenin Cross-Reactivity with G12 Antibody in a Wide Range of Current Oat Cultivars.Foods (Basel, Switzerland) · 2022Article
- Effect of additional water supply during grain filling on protein composition and epitope characteristics of winter oats.Current research in food science · 2022Article
- Development of a Sequence Searchable Database of Celiac Disease-Associated Peptides and Proteins for Risk Assessment of Novel Food Proteins.Frontiers in allergy · 2022Article
- "The Gluten-Free Diet and Its Relationship with Metabolic Syndrome: Dietary Friend or Foe?"Current nutrition reports · 2021Review
- A Novel Sprouted Oat Fermented Beverage: Evaluation of Safety and Health Benefits for Celiac Individuals.Nutrients · 2021Article
- Review
- Quality of Life Prior and in the Course of the COVID-19 Pandemic: A Nationwide Cross-Sectional Study with Brazilian Dietitians.International journal of environmental research and public health · 2021Article
- Investigation of Protein and Epitope Characteristics of Oats and Its Implications for Celiac Disease.Frontiers in nutrition · 2021Article
- Oats as a Safe Alternative to Triticeae Cereals for People Suffering from Celiac Disease? A Review.Plant foods for human nutrition (Dordrecht, Netherlands) · 2020Review
- Amino Acid Composition of Novel Plant Drinks from Oat, Lentil and Pea.Foods (Basel, Switzerland) · 2020Article
- Combined Liquid Chromatography-mass Spectrometry and Next-generation DNA Sequencing Detection of Adulterants and Contaminants in Analgesic and Anti-inflammatory Herbal Medicines.Pharmaceutical medicine · 2020Article
- Mapping Coeliac Toxic Motifs in the Prolamin Seed Storage Proteins of Barley, Rye, and Oats Using a Curated Sequence Database.Frontiers in nutrition · 2020Article
- The Gluten-Free Diet: Use in Digestive Disease Management.Current treatment options in gastroenterology · 2019Review
- To Be Oats or Not to Be? An Update on the Ongoing Debate on Oats for Patients With Celiac Disease.Frontiers in pediatrics · 2019Review
- Gluten Immunogenic Peptides as Standard for the Evaluation of Potential Harmful Prolamin Content in Food and Human Specimen.Nutrients · 2018Review
- Potential role of the IL-33/ST2 axis in celiac disease.Cellular & molecular immunology · 2017Article
- Characterization of celiac disease related oat proteins: bases for the development of high quality oat varieties suitable for celiac patients.Scientific reports · 2017Article
- Properties of Gluten Intolerance: Gluten Structure, Evolution, Pathogenicity and Detoxification Capabilities.Nutrients · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A strict gluten-free diet (GFD) is the only currently available therapeutic treatment for patients with celiac disease (CD). Traditionally, treatment with a GFD has excluded wheat, barley and rye, while the presence of oats is a subject of debate. The most-recent research indicates that some cultivars of oats can be a safe part of a GFD. In order to elucidate the toxicity of the prolamins from oat varieties with low, medium, and high CD toxicity, the avenin genes of these varieties were cloned and sequenced, and their expression quantified throughout the grain development. At the protein level, we have accomplished an exhaustive characterization and quantification of avenins by RP-HPLC and an analysis of immunogenicity of peptides present in prolamins of different oat cultivars. Avenin sequences were classified into three different groups, which have homology with S-rich prolamins of Triticeae. Avenin proteins presented a lower proline content than that of wheat gliadin; this may contribute to the low toxicity shown by oat avenins. The expression of avenin genes throughout the development stages has shown a pattern similar to that of prolamins of wheat and barley. RP-HPLC chromatograms showed protein peaks in the alcohol-soluble and reduced-soluble fractions. Therefore, oat grains had both monomeric and polymeric avenins, termed in this paper gliadin- and glutenin-like avenins. We found a direct correlation between the immunogenicity of the different oat varieties and the presence of the specific peptides with a higher/lower potential immunotoxicity. The specific peptides from the oat variety with the highest toxicity have shown a higher potential immunotoxicity. These results suggest that there is wide range of variation of potential immunotoxicity of oat cultivars that could be due to differences in the degree of immunogenicity in their sequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.